These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 17501937)

  • 1. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
    Feuer EJ; Mariotto A; Merrill R
    Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 16. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receiver operating characteristics of the prostate specific antigen test in an unselected population.
    McLernon DJ; Donnan PT; Gray M; Weller D; Sullivan F
    J Med Screen; 2006; 13(2):102-7. PubMed ID: 16792835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
    Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
    Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is prostate cancer screening justified in the Bedouin population?
    Abdallah M; Lazarev I; Ariad S; Mermershtain W
    Onkologie; 2009 May; 32(5):260-2. PubMed ID: 19420972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.